Research Analysts Offer Predictions for GoodRx Holdings, Inc.’s FY2024 Earnings (NASDAQ:GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRX) – Research analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for GoodRx in a research report issued to clients and investors on Tuesday, October 1st. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.13 per share for the year, down from their prior forecast of $0.14. The consensus estimate for GoodRx’s current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for GoodRx’s Q1 2025 earnings at $0.05 EPS, Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.06 EPS and FY2026 earnings at $0.30 EPS.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The firm had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. During the same period in the previous year, the company earned $0.02 EPS. GoodRx’s revenue was up 5.7% compared to the same quarter last year.

GDRX has been the subject of several other research reports. Morgan Stanley increased their price target on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of GoodRx in a research report on Friday, August 16th. Citigroup lowered their price objective on GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, UBS Group lowered their price objective on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, GoodRx presently has a consensus rating of “Moderate Buy” and an average price target of $9.36.

GoodRx Price Performance

NASDAQ:GDRX opened at $6.88 on Wednesday. GoodRx has a one year low of $4.14 and a one year high of $9.26. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. The stock has a market cap of $2.58 billion, a PE ratio of -688.00, a P/E/G ratio of 3.38 and a beta of 1.37. The stock has a 50 day moving average price of $7.66 and a 200 day moving average price of $7.57.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.17% of the stock is currently owned by company insiders.

Institutional Trading of GoodRx

A number of hedge funds and other institutional investors have recently bought and sold shares of GDRX. Cornercap Investment Counsel Inc. increased its position in shares of GoodRx by 1.7% during the second quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after purchasing an additional 1,266 shares in the last quarter. California State Teachers Retirement System increased its position in shares of GoodRx by 5.1% during the first quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock worth $503,000 after purchasing an additional 3,444 shares in the last quarter. US Bancorp DE increased its position in shares of GoodRx by 3.7% during the first quarter. US Bancorp DE now owns 109,818 shares of the company’s stock worth $780,000 after purchasing an additional 3,877 shares in the last quarter. Beacon Capital Management LLC acquired a new stake in shares of GoodRx during the first quarter worth about $28,000. Finally, Plato Investment Management Ltd acquired a new stake in shares of GoodRx during the second quarter worth about $43,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.